Shire logo

Baxalta/Shire, a global leader in biologic medical therapies, is building a state-of-the-art manufacturing facility in Stanton Springs to support growth of its plasma-based treatments used for immune disorders, trauma and other critical conditions.

Baxalta/Shire expects its capital investments at Stanton Springs to exceed $1 billion, resulting in more than 1,500 new full-time positions in Georgia and another 500+ across multiple U.S. locations.

In 2015, construction began on operations supporting plasma fractionation, purification, fill-finish and a testing lab. Commercial production is scheduled to begin in 2018, with the new plasma fractionation facility adding up to three million liters of new capacity annually when fully operational. The facility will have the flexibility and necessary infrastructure to expand further to support additional global market needs.

For more information about Shire visit www.shire.com

  • 1-million-square-foot manufacturing facility
  • 160 acres in Stanton Springs with additional plasma collection centers around Georgia
  • 1,500 jobs over the next 5 years, over 600 employees currently on-site
  • $60,000 average annual salary
  • $1 billion investment over 5 years
  • Voted Deal of the Year (2012) by Georgia Economic Developers Association (GEDA)
  • Voted NAIOP 2012 Industrial Deal of the Year
shire_georgia_june_aerial_nw_far1024
shire_georgia_june_aerial_n-1024
shire_georgia_june_aerial_nw_close-1024
shire_georgia_june_aerial_nw_far-1024

Georgia Governor Nathan Deal welcomes Baxalta/Shire to Georgia at the facility’s groundbreaking ceremony in 2012

August 2012: Community, company and state officials break ground for Baxalta/Shire’s $1 billion Georgia bioscience facility

Jackie Rohosky, TCSG assistant commissioner for economic development programs and head of Quick Start; Scott Joost, Baxalta director of manufacturing; and Calvin Klitz, Baxalta director of human resources, review progress during the construction of the Georgia Bioscience Training Center